Hilder Mercado-la Peira, José Dussan-Ordoñez, Antistio Alvíz-amador et al.
Study molecular of interaction between N,N-dimethyltryptamine analogs (DMT) with 5-HT1A and 5-HT1B receptors. Likewise, complexes mechanisms that related the interaction with these receptors involved in alterations such as depression, post-traumatic stress disorders and anxiety. Therefore, have been evaluated the activity of DMT analogs by docking molecular studies in the determination of the...
Sophie Holland
This paper explores ketamine as a psychedelic alongside the differential impacts of psychedelic versus psycholytic effects of ketamine in a therapeutic setting. The paper examines existing research to elucidate the broad therapeutic potential of ketamine and the mechanisms underlying each modality. The primary objective is to present the differences between psychedelic and psycholytic...
Lena K L Oestreich, Hugh McGovern, Zohaib Nadeem et al.
preprint
Background: The therapeutic use of 3,4-methylenedioxymethamphetamine (MDMA) and psilocybin has gained interest due to their potential efficacy in treating mental illness. We systematically reviewed the efficacy of MDMA and psilocybin in treating mental illness and explored the moderating effects of dosage, psychotherapeutic support, and concurrent antidepressant use. Methods: In this systematic...
Heather M Hall
preprint
Anomalous self-experiences (ASEs) and basic self-disturbance have been proposed as core, and specific, markers of schizophrenia-spectrum disorders (SSD), operationalized through instruments such as the Examination of Anomalous Self-Experience (EASE). Many of the phenomena grouped under the ASE construct, derealization, depersonalization, altered embodiment, unstable self–world boundaries,...
Sofia Hebel
Defined by numerous mental and physical constituents, health behavior change can be directly influenced by Mindfulness-Based Interventions (MBIs). Neurological and psychological evi- dence suggest positive correlations between yoga and meditation practice and decreased anxiety symptomatology by individuals of domestic violence. Regulatory processes, implemented via Mindfulness-Based Cognitive...
Vincent Joralemon
preprint
As psychedelic-assisted therapies advance through the FDA approval pipeline, the question of who will pay for them is moving from academic to urgent. Experts project that MDMA-assisted therapy for PTSD will cost upwards of $11,000-$12,000 per course of treatment-a price tag that, absent insurance, places these therapies out of reach for many of the patients most likely to benefit. This essay...
Nathaniel Martin
preprint
A disease-first off-patent drug-repurposing engine identified dextromethorphan (DXM) as a compound that could lower the risk of post-traumatic stress disorder (PTSD) when administered soon after exposure to severe stress. DXM combines anti-inflammatory activity, N-methyl-D-aspartate (NMDA) receptor antagonism, sigma-1 receptor agonism, and monoamine re-uptake inhibition, a profile that targets...
Nimrod Polak, Ephraim S. Grossman
preprint
Abstract Background Individuals with specific learning disabilities (SLD) often experience significant emotional challenges arising from negative learning experiences. Mindfulness interventions may provide support in addressing these difficulties. Objective This study examined how mindfulness, cultivated through an MBSR intervention, influences stress-related symptoms among individuals with...
Harman Brar
Virtual reality has recently been utilized in a therapeutic tool within the area of psychotherapy. VR therapy has become a significant approach to a number of psychological disorders such as anxiety, PTSD, and depression through exposure therapy and simulated environments (Park et al., 2019). However, the potential to mimic psychedelic experiences through VR simulations as a therapeutic...
Eduardo Ekman Schenberg
preprint
Between April and October 2024, expert bodies in two countries reached strikingly opposite conclusions about the therapeutic use of 3,4-methylenedioxymethamphetamine (MDMA). On the one hand, the Food and Drug Administration in the USA rejected a formal New Drug Application from a specific drug sponsor, Lykos Therapeutics, for Post-Traumatic Stress Disorder (PTSD). The decision was surprising to...